Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Summary of publications:
Publications (original articles or review articles) published in 2020 from OUS - Section for Cellular Therapy
12 publications found
Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology
Methods Mol Biol, 2115, 445-454
SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy
Scand J Immunol, 92 (4), e12917
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther, 29 (3), 1199-1213
Colorectal cysts as a validating tool for CAR therapy
BMC Biotechnol, 20 (1), 30
Long-term surviving cancer patients as a source of therapeutic TCR
Cancer Immunol Immunother, 69 (5), 859-865
Sympathetic improvement of cancer vaccine efficacy
Hum Vaccin Immunother, 16 (8), 1888-1890
A Small-Molecule Tankyrase Inhibitor Reduces Glioma Stem Cell Proliferation and Sphere Formation
Cancers (Basel), 12 (6)
Combinatorial CAR design improves target restriction
J Biol Chem, 296, 100116
Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial
Clin Transl Immunology, 9 (3), e1117
Next Generation of Adoptive T Cell Therapy Using CRISPR/Cas9 Technology: Universal or Boosted?
Methods Mol Biol, 2115, 407-417
Posttransplantation Lymphoproliferative Disease Treated by Retransplantation
Case Reports Immunol, 2020, 9403123
T cell receptor therapy against melanoma-Immunotherapy for the future?
Scand J Immunol, 92 (4), e12927